[go: up one dir, main page]

PE105699A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
PE105699A1
PE105699A1 PE1998000735A PE00073598A PE105699A1 PE 105699 A1 PE105699 A1 PE 105699A1 PE 1998000735 A PE1998000735 A PE 1998000735A PE 00073598 A PE00073598 A PE 00073598A PE 105699 A1 PE105699 A1 PE 105699A1
Authority
PE
Peru
Prior art keywords
hydroxyluene
azaesteroid
preference
composition
acid
Prior art date
Application number
PE1998000735A
Other languages
English (en)
Inventor
Alan Frank Parr
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE105699A1 publication Critical patent/PE105699A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE a)4-AZAESTEROIDE o 6-AZAESTEROIDE, DE PREFERENCIA CARBONIL-4-AZAANDROST-1-EN-3-ONA 17-�-SUSTITUIDO o CARBONIL-6-AZAANDROST-1-EN-3-ONA 17-�-SUSTITUIDO; b)UN ESTER DE ACIDO GRASO DE GLICEROL O PROPILENGLICOL, SIENDO LOS ACIDOS CARBOXILICOS DE C6-C12, DE PREFERENCIA ES UN MONOESTER, LA COMPOSICION COMPRENDE ADEMAS UN ANTIOXIDANTE TAL COMO HIDROXITOLUENO BUTILADO, HIDROXIANISOLBUTILADO, ACIDO ASCORBICO O SUS MEZCLAS. LA COMPOSICION SE PRESENTA DE PREFERENCIA EN UNA CAPSULA DE GELATINA BLANDA. EL AZAESTEROIDE ES UN INHIBIDOR DE LA ENZIMA TESTOSTERONA 5-ALFA REDUCTASA, POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE HIPERPLASIA PROSTATICA BENIGNA, CANCER DE LA PROSTATA
PE1998000735A 1997-08-19 1998-08-14 Composicion farmaceutica PE105699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9717428.8A GB9717428D0 (en) 1997-08-19 1997-08-19 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
PE105699A1 true PE105699A1 (es) 1999-11-25

Family

ID=10817619

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000735A PE105699A1 (es) 1997-08-19 1998-08-14 Composicion farmaceutica

Country Status (15)

Country Link
EP (1) EP1007010A2 (es)
JP (1) JP2002511101A (es)
KR (1) KR20010014080A (es)
CN (1) CN1263461A (es)
AR (1) AR016629A1 (es)
AU (1) AU9343098A (es)
BR (1) BR9810458A (es)
CA (1) CA2295016A1 (es)
CO (1) CO4960657A1 (es)
GB (1) GB9717428D0 (es)
MA (1) MA26531A1 (es)
PE (1) PE105699A1 (es)
TR (1) TR199903209T2 (es)
WO (1) WO1999008666A2 (es)
ZA (1) ZA987392B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
CN102552917A (zh) 2003-08-13 2012-07-11 比奥孔有限公司 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂
WO2005066195A1 (de) * 2004-01-02 2005-07-21 Pharmacon Forschung Und Beratung Gmbh Verfahren zur herstellung von 1,2-ungesättigten azasteroiden
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US8900631B2 (en) 2011-04-28 2014-12-02 Health Science Funding, LLC Dosage form to increase prasterone bioavailability
CN103169712B (zh) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 提高生物利用度的度他雄胺制剂及其制备方法
WO2014002015A1 (en) 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition comprising dutasteride
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
KR101679992B1 (ko) 2015-12-31 2016-11-28 주식회사 유유제약 프로필렌글리콜 모노라우레이트를 포함하는 두타스테리드의 약학적 조성물 및 이의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss

Also Published As

Publication number Publication date
WO1999008666A3 (en) 1999-04-15
CN1263461A (zh) 2000-08-16
KR20010014080A (ko) 2001-02-26
CO4960657A1 (es) 2000-09-25
AR016629A1 (es) 2001-07-25
AU9343098A (en) 1999-03-08
WO1999008666A2 (en) 1999-02-25
GB9717428D0 (en) 1997-10-22
ZA987392B (en) 2000-02-17
EP1007010A2 (en) 2000-06-14
BR9810458A (pt) 2000-09-05
TR199903209T2 (xx) 2000-05-22
MA26531A1 (fr) 2004-12-20
CA2295016A1 (en) 1999-02-25
JP2002511101A (ja) 2002-04-09

Similar Documents

Publication Publication Date Title
PE105699A1 (es) Composicion farmaceutica
CO5210857A1 (es) Composicion farmaceutica de orlistat y esteres de acidos de grasos de polioles
AR004213A1 (es) Composicion antitranspirante en gel y aerosol y metodo para tratar o prevenir el mal olor asociado con la transpiracion.
UY24737A1 (es) Composiciones cosmeticas
AR013459A1 (es) Composiciones dermatologicas y/o cosmeticas.
DE69231991D1 (de) Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
PL350094A1 (en) Oral liquid pharmacological compositions containing long-chain triglycerides and lipophylic surfactants
ES2058515T3 (es) Composicion enzimatica detergente y blanqueante.
ZA973653B (en) Pharmaceutical compositions.
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
PT823897E (pt) Esteres de acido nicotico e composicoes farmaceuticas que os contem
ES553499A0 (es) Un procedimiento para preparar una composicion que contiene ubidecarenona
ES2140512T3 (es) Composiciones farmaceuticas que contienen derivados de estaurosporina y un gliceridos polialquilenglicolico.
MXPA03009342A (es) Alcoholes graso anti-inflamatorios y esteres de acido graso utiles como portadoes de antigeno.
DE50305781D1 (de) Wasserbeständige mascara-zusammensetzung mit hohem wassergehalt
PE97199A1 (es) Composiciones solubilizadas de sertralina
ATE24191T1 (de) Alkydharze, enthaltend ringoeffnungsprodukte epoxidierter fettalkohole oder fettsaeurederivate als hydroxylverbindungen.
ES2151052T3 (es) Fraccionamiento de aceites trigliceridos.
BR0016204A (pt) Composição
ES2143281T3 (es) Procedimiento de transesterificacion para la preparacion de dihidromircenol y de mircenol.
ES2135568T3 (es) Composiciones veterinarias de liberacion sostenida que contienen tilosina.
AR000164A1 (es) Composición no acuosa apta para liberar acroleina cuando es puesta en contacto con agua util para combatir organismos nocivos microbianos vegetales y animales y el procedimiento aplicación de dicha composición
CO2025010115A2 (es) Composiciones antitranspirantes
ECSP003653A (es) Formulaciones solidas de lipido
UY26337A1 (es) Formulaciones de lipidos solidos

Legal Events

Date Code Title Description
FC Refusal